Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997017067) SUBLINGUAL AND BUCCAL ADMINISTRATION OF SELEGILINE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/017067 International Application No.: PCT/US1996/017745
Publication Date: 15.05.1997 International Filing Date: 05.11.1996
Chapter 2 Demand Filed: 14.04.1997
IPC:
A61K 31/137 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
137
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Applicants:
SOMERSET PHARMACEUTICALS, INC. [US/US]; 5415 West Laurel Street Tampa, FL 33607-1729, US (AllExceptUS)
DiSANTO, Anthony, R. [US/US]; US (UsOnly)
Inventors:
DiSANTO, Anthony, R.; US
Agent:
SANZO, Michael, A.; Vinson & Elkins 1455 Pennsylvania Avenue N.W. Washington, DC 20004-1008, US
GILL JENNINGS & EVERY; Broadgate House 7 Eldon Street London EC2M 7LH, GB
Priority Data:
60/007,32506.11.1995US
Title (EN) SUBLINGUAL AND BUCCAL ADMINISTRATION OF SELEGILINE
(FR) ADMINISTRATION SUBLINGUALE ET BUCCALE DE SELEGILINE
Abstract:
(EN) The present invention is directed to improved methods for treating certain selegiline-responsive diseases or conditions and, more specifically, to methods in which selegiline is administered buccally or sublingually. Selegiline may be used either as a free base or as a pharmaceutically acceptable acid addition salt. The selegiline-responsive diseases or conditions include neuronal-degenerative diseases and conditions, such as Alzheimer's disease and neuronal damage from hypoxia, stroke, ischemia, and trauma, and dopaminergic-related, selegiline responsive diseases and conditions such as depression and ADHD.
(FR) L'invention concerne des procédés améliorés utilisés pour traiter certaines maladies ou états réagissant à la sélégiline et, plus particulièrement, des procédés consistant à administrer la sélégiline par voie buccale ou sublinguale. On peut utiliser la sélégiline soit en tant que base libre, soit en tant que sel d'addition d'acide acceptable sur le plan pharmaceutique. Les maladies ou états réagissant à la sélégiline comprennent les maladies neurodégénératives, telles que la maladie d'Alzheimer et les détériorations neuronales provoquées par l'hypoxie, l'attaque, l'ischémie et le trauma, ainsi que des maladies de type dopaminergique réagissant à la sélégiline, telles que la dépression et l'hyperactivité avec déficit de l'attention (ADHD).
Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NO19982044EP0866691JPH11504944CN1207675CA2236368AU1996076080
DK0866691